Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.
about
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of PlasmodiumInteraction of Cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivoEnhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells.Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses.Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in miceInduction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculationIn vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunityAlternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation.Generation of recombinant porcine parvovirus virus-like particles in Saccharomyces cerevisiae and development of virus-specific monoclonal antibodiesIn vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 GUse of the baculovirus expression system for the generation of virus-like particles.Characterization of a permissive epitope insertion site in adenovirus hexonExploiting viral properties for the rational design of modern vaccines.Virus-like particles of chimeric recombinant porcine circovirus type 2 as antigen vehicle carrying foreign epitopes.A novel recombinant pseudorabies virus expressing parvovirus VP2 gene: Immunogenicity and protective efficacy in swine.Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice.A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosisVaccines that facilitate antigen entry into dendritic cells.Induction of immune responses in mice after intragastric administration of Lactobacillus casei producing porcine parvovirus VP2 protein.CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.Cross-linked protein crystals for vaccine deliveryNovel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.Clinical applications of virosomes in cancer immunotherapy.Virus-like particles: flexible platforms for vaccine development.Biological gene delivery vehicles: beyond viral vectors.Virus-like particle vaccines and adjuvants: the HPV paradigm.Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.Expression and characterization of hepatitis E virus-like particles and non-virus-like particles from insect cells.Advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine researchCell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response.In vitro disassembly of a parvovirus capsid and effect on capsid stability of heterologous peptide insertions in surface loops.Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells.Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity.Current Status of Rift Valley Fever Vaccine Development.Influence of minor displacements in loops of the porcine parvovirus VP2 capsid on virus-like particles assembly and the induction of antibody responses.A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant.Replication-incompetent rabies virus vector harboring glycoprotein gene of lymphocytic choriomeningitis virus (LCMV) protects mice from LCMV challenge.
P2860
Q28730541-6417A1F2-7489-412D-A30D-963BE321A311Q33517131-937E27A1-5A31-4356-96D0-6115A25C1017Q33605386-EBC21D69-A2B6-4DBD-B8A7-8822D264D25CQ33643167-7C588E60-5142-4C07-9E01-DCC0E1F9B8C1Q33717736-BFB3A628-164D-41C4-BB76-40D26B96C2E9Q33788701-56D85F82-3637-4E16-BD9F-D9C4D18B43B7Q33806244-3701704E-C5C4-4F58-9919-BA4990B2798AQ33815400-F1392FF7-3DF0-47A9-8437-04EFCC01588FQ33874062-C3437809-24F9-490F-9314-DCF2667A7500Q33931622-25979CED-DB6A-471C-8350-E72AF8642266Q34342982-DD2AE57E-38E2-4AC4-B7F9-9C9D4791C2CFQ34351909-5AA03898-457B-46D4-99FE-F1317BB68F45Q34648067-F18ABFF0-D826-49BE-B7A0-BED0C0D9F7F9Q34746490-A41ABA5D-362D-4451-AC7D-81D2BC884D4EQ34774771-F78BFABA-C794-4EC0-97FE-F1694DC7187BQ35089268-D1096FBC-3417-4CF9-BE5F-E2DBF701170AQ35128995-0E2C3287-4700-4744-B65C-544D88F66B7AQ35196530-F00509B2-6E70-4BE5-8CC5-B00DD05A3F5BQ35300720-8C580AF9-4F4E-43A8-9E93-EECB9789E72FQ35915763-4D0B19CC-985F-4DC2-8FE5-18EE4E758CFAQ36136940-F6F44C50-04C4-4EE9-AF27-2A6E0185AAE6Q36370281-D3943BEE-2F31-4EF9-A2E6-2E19FC20ADEBQ36420836-B297ED20-C122-443B-89BA-1AB473EB8A3BQ36424493-585D4830-F286-4D48-AD36-FB76A09975EBQ36627236-E8CFEA60-6C4E-4D3A-87B4-4A5CEE30D0CAQ36837144-2765B5EE-3A32-4FB4-8BE5-8203AC4A10B0Q37412239-AA91658B-2764-40A6-912A-370DC9D4603FQ37608311-784C11B8-E356-4796-8AF8-61941F33816AQ37792984-CC458A7A-9B02-42BB-8BB8-5AF5C26B5068Q38396830-04DFC581-464C-47BD-8F01-CE4A9A648E73Q39526556-1587302B-6033-4FD0-9365-5DFD89E4103DQ40066002-FC2DC62C-3546-40FC-82B9-7BC33275B239Q40609806-612141FD-CC9E-4FF8-AA35-A92741D27607Q40700979-AC7433B2-38A6-4014-8697-DC1754C5E0F6Q40805568-C2BB97AC-9CD4-42E4-865C-AFDEF9D2A6A4Q41877558-4D632041-062F-46CD-8F46-DCE0F56A85E7Q41929716-91032DDE-2F02-457B-BEFA-0C991B937342Q45336285-FAD053F4-C24F-4B2B-AFDC-70A8641A91F5Q45756479-A75591E5-016C-4CE4-A4CD-760C69688D1EQ52586088-349D38E2-6408-40E5-8819-FB972FEABF7D
P2860
Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Recombinant parvovirus-like pa ...... e antiviral cytotoxic T cells.
@ast
Recombinant parvovirus-like pa ...... e antiviral cytotoxic T cells.
@en
type
label
Recombinant parvovirus-like pa ...... e antiviral cytotoxic T cells.
@ast
Recombinant parvovirus-like pa ...... e antiviral cytotoxic T cells.
@en
prefLabel
Recombinant parvovirus-like pa ...... e antiviral cytotoxic T cells.
@ast
Recombinant parvovirus-like pa ...... e antiviral cytotoxic T cells.
@en
P2093
P2860
P356
P1476
Recombinant parvovirus-like pa ...... ve antiviral cytotoxic T cells
@en
P2093
P2860
P304
P356
10.1073/PNAS.94.14.7503
P407
P577
1997-07-01T00:00:00Z